乌利莫瑞林与甲氧氯普胺治疗危重患者肠内喂养不耐受的多中心随机双盲研究:PROMOTE试验
PROMOTE试验为多中心、随机、双盲研究,纳入120例胃残余量≥500 ml诊断肠内喂养不耐受的ICU患者,按1:1随机接受乌利莫瑞林(62例)或甲氧氯普胺(58例)治疗5天,采用容量为基础喂养方案和标准化肠内配方。主要终点为5天内实际接受蛋白处方百分比(%DPP),乌利莫瑞林组中位数82.9% vs 甲氧氯普胺组82.3%,p=0.49,无统计学差异。排除非喂养相关终止后5天喂养成功率分别为67.7%和70.6%,所有次要终点和不良事件两组均无差异。作者结论为两种促动力药喂养成功率相似且安全性无差异。
要点
- 研究纳入胃残余量≥500 ml诊断肠内喂养不耐受的ICU患者,乌利莫瑞林62例与甲氧氯普胺58例,治疗5天。
- 主要终点5天%DPP中位数乌利莫瑞林组82.9%(Q1 38.4%,Q3 100.2%)vs 甲氧氯普胺组82.3%(Q1 65.6%,Q3 100.2%),p=0.49。
- 排除非喂养相关终止后5天喂养成功率乌利莫瑞林组67.7% vs 甲氧氯普胺组70.6%,两组无差异。
- 所有次要终点(胃排空、复发不耐受、呕吐或反流、误吸、肺部感染)及不良事件两组均无差异。
- 两组患者平均APACHE II评分21.6分、SOFA评分8.6分,63.3%因内科原因入住ICU。
适用人群与场景
- ICU患者,以胃残余量≥500 ml诊断肠内喂养不耐受;平均APACHE II 21.6分、SOFA 8.6分,63.3%为内科原因入住ICU。
- 研究采用容量为基础喂养方案和标准化肠内配方,随机接受乌利莫瑞林或甲氧氯普胺治疗5天。
诊断标准与关键阈值
- 肠内喂养不耐受诊断标准:胃残余量(GRV)≥500 ml。
处置流程与药物剂量
- 乌利莫瑞林与甲氧氯普胺均用于肠内喂养不耐受的ICU患者,疗程5天,研究方案采用容量为基础喂养和标准化肠内配方。
研究设计与关键结果
- 多中心、随机、双盲研究,120例ICU肠内喂养不耐受患者随机1:1接受乌利莫瑞林(62例)或甲氧氯普胺(58例)治疗5天。
- 主要终点5天%DPP中位数:乌利莫瑞林组82.9%(Q1 38.4%,Q3 100.2%)vs 甲氧氯普胺组82.3%(Q1 65.6%,Q3 100.2%),p=0.49。
- 排除非喂养相关终止后5天喂养成功率(80% DPP):乌利莫瑞林组67.7% vs 甲氧氯普胺组70.6%。
- 所有次要终点(胃排空经对乙酰氨基酚吸收评估、复发不耐受GRV≥500 ml、呕吐或反流、误吸经气管吸出物胃蛋白酶阳性定义、肺部感染)两组无差异,不良事件无差异。
证据类型、等级与局限
- 证据类型:多中心随机双盲研究(PROMOTE试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于胃残余量≥500 ml诊断肠内喂养不耐受的ICU患者,乌利莫瑞林与甲氧氯普胺在5天%DPP和喂养成功率上效果相似,安全性无差异,作者结论为两者喂养成功率相似且无安全性差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Enteral feeding intolerance (EFI) is a frequent problem in the intensive care unit (ICU), but current prokinetic agents have uncertain efficacy and safety profiles. The current study compared the efficacy and safety of ulimorelin, a ghrelin agonist, with metoclopramide in the treatment of EFI.
METHODS: One hundred twenty ICU patients were randomized 1:1 to ulimorelin or metoclopramide for 5 days. EFI was diagnosed by a gastric residual volume (GRV) ≥ 500 ml. A volume-based feeding protocol was employed, and enteral formulas were standardized. The primary end point was the percentage daily protein prescription (%DPP) received by patients over 5 days of treatment. Secondary end points included feeding success, defined as 80% DPP; gastric emptying, assessed by paracetamol absorption; incidences of recurrent intolerance (GRV ≥ 500 ml); vomiting or regurgitation; aspiration, defined by positive tracheal aspirates for pepsin; and pulmonary infection.
RESULTS: One hundred twenty patients were randomized and received the study drug (ulimorelin 62, metoclopramide 58). Mean APACHE II and SOFA scores were 21.6 and 8.6, and 63.3% of patients had medical reasons for ICU admission. Ulimorelin and metoclopramide resulted in comparable %DPPs over 5 days of treatment (median [Q1, Q3]: 82.9% [38.4%, 100.2%] and 82.3% [65.6%, 100.2%], respectively, p = 0.49). Five-day rates of feeding success were 67.7% and 70.6% when terminations unrelated to feeding were excluded, and there were no differences in any secondary outcomes or adverse events between the two groups.
CONCLUSIONS: Both prokinetic agents achieved similar rates of feeding success, and no safety differences between the two treatment groups were observed.
参考来源
- Heyland DK, van Zanten ARH, Grau-Carmona T, et al. A multicenter, randomized, double-blind study of ulimorelin and metoclopramide in the treatment of critically ill patients with enteral feeding intolerance: PROMOTE trial. Intensive Care Med. 2019. PMID: 31062046. doi:10.1007/s00134-019-05593-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。